Document is current
Any future updates will be listed below
-
Authors
Do, Hackwon
Li, Zhong-Rui
Tripathi, Praveen Kumar
Mitra, Sonali
Guerra, Stephanie
Dash, Ananya https://orcid.org/0000-0001-5679-1065
Weerasekera, Dulanthi
Makthal, Nishanth
Shams, Syed
Aggarwal, Shifu
Singh, Bharat Bhushan
Gu, Di https://orcid.org/0000-0003-4860-7701
Du, Yongle
Olsen, Randall J.
LaRock, Christopher https://orcid.org/0000-0003-3035-5331
Zhang, Wenjun https://orcid.org/0000-0001-9348-972X
Kumaraswami, Muthiah https://orcid.org/0000-0002-9959-5598
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI146048, R01AI162748, R01 AI153071)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI153071, DP2AT009148)
- License Information
-
More Information
Article History
Received: 21 April 2023
Accepted: 11 December 2023
First Online: 16 January 2024
Competing interests
: The Houston Methodist Research Institute (M.K.) and University of California, Berkeley (W.Z.) have jointly filed a provisional patent application that includes the compound salivabactin and derivatives thereof, as well as the utilization of eSAL for the prevention of GAS infections. All other authors declare no competing interests.
